Benitec Biopharma Shares Are Trading Higher. The Company Announced a $40 Million Oversubscribed Private Placement Financing and Reported Interim Clinical Data for the First OPMD Subject Treated With BB-301 in Its Phase 1b/2a Study
贝尼特克生物制药公司股价走高。该公司宣布了4000万澳元的超额认购私募融资，并报告了其1b/2a期研究中首位接受 BB-301 治疗的OPMD受试者的中期临床数据